Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Share-based Compensation (2016 - 2025)

Fennec Pharmaceuticals filings provide 15 years of Share-based Compensation readings, the most recent being $2.5 million for Q4 2025.

  • On a quarterly basis, Share-based Compensation rose 124.38% to $2.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $7.0 million, a 38.96% increase, with the full-year FY2025 number at $7.0 million, up 38.96% from a year prior.
  • Share-based Compensation hit $2.5 million in Q4 2025 for Fennec Pharmaceuticals, up from $2.2 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $2.5 million in Q2 2023 to a low of $30000.0 in Q4 2022.
  • Median Share-based Compensation over the past 5 years was $1.1 million (2023), compared with a mean of $1.2 million.
  • Biggest five-year swings in Share-based Compensation: skyrocketed 6214.29% in 2021 and later plummeted 94.21% in 2022.
  • Fennec Pharmaceuticals' Share-based Compensation stood at $917000.0 in 2021, then tumbled by 96.73% to $30000.0 in 2022, then skyrocketed by 2756.67% to $857000.0 in 2023, then skyrocketed by 31.16% to $1.1 million in 2024, then soared by 124.38% to $2.5 million in 2025.
  • The last three reported values for Share-based Compensation were $2.5 million (Q4 2025), $2.2 million (Q3 2025), and $1.5 million (Q2 2025) per Business Quant data.